Author:
Reichmann Heinz,Bilsing Anja,Ehret Reinhard,Greulich Wolfgang,Schulz Jörg B.,Schwartz Andreas,Rascol Olivier
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Reference22 articles.
1. Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey Jr. RB (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301–304
2. Dhawan V,Medcalf P, Stegie F, Jackson G, Basu S, Luce P,Odin P, Chaudhuri KR (2005) Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline. J Neural Transm 112:661–668
3. Eggert K, Odin P, Gasser T,Meinertz T, Strasser R, Osterspey A, Deuschl G, Oertel WH (2005) Fachgerechter Einsatz von Dopamin-Agonisten. Deutsches Ärzteblatt 102:B22–B23
4. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JH, Abbaszade I, Hollis JM, Largent BI, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75–81
5. Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration’s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730–731
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献